Research Analysts Set Expectations for Sutro Biopharma, Inc.’s Q1 2025 Earnings (NASDAQ:STRO)

Sutro Biopharma, Inc. (NASDAQ:STRO) – Wedbush issued their Q1 2025 EPS estimates for Sutro Biopharma in a report issued on Tuesday, March 26th. Wedbush analyst D. Nierengarten expects that the company will post earnings per share of ($0.83) for the quarter. Wedbush has a “Outperform” rating and a $8.00 price target on the stock. The consensus estimate for Sutro Biopharma’s current full-year earnings is ($3.23) per share. Wedbush also issued estimates for Sutro Biopharma’s Q2 2025 earnings at ($0.88) EPS, Q3 2025 earnings at ($0.74) EPS and Q4 2025 earnings at ($0.76) EPS.

Several other research firms have also commented on STRO. JMP Securities reissued a “market outperform” rating and issued a $17.00 target price on shares of Sutro Biopharma in a report on Tuesday. Oppenheimer reiterated an “outperform” rating and set a $10.00 target price on shares of Sutro Biopharma in a research report on Wednesday. Finally, HC Wainwright cut their target price on shares of Sutro Biopharma from $16.00 to $12.00 and set a “buy” rating on the stock in a research report on Tuesday. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $13.71.

Sutro Biopharma Stock Up 14.6 %

STRO stock opened at $5.65 on Wednesday. Sutro Biopharma has a 12 month low of $2.01 and a 12 month high of $6.13. The firm has a market cap of $352.79 million, a P/E ratio of -3.17 and a beta of 0.95. The company’s 50-day moving average price is $4.50 and its two-hundred day moving average price is $3.79.

Institutional Trading of Sutro Biopharma

Hedge funds have recently modified their holdings of the stock. Nisa Investment Advisors LLC increased its stake in shares of Sutro Biopharma by 14,125.8% in the 4th quarter. Nisa Investment Advisors LLC now owns 8,820 shares of the company’s stock valued at $38,000 after acquiring an additional 8,758 shares in the last quarter. Wells Fargo & Company MN increased its stake in shares of Sutro Biopharma by 331.7% in the 4th quarter. Wells Fargo & Company MN now owns 5,690 shares of the company’s stock valued at $46,000 after acquiring an additional 4,372 shares in the last quarter. Point72 Hong Kong Ltd bought a new stake in shares of Sutro Biopharma in the 2nd quarter valued at $46,000. Tower Research Capital LLC TRC increased its stake in shares of Sutro Biopharma by 342.3% in the 3rd quarter. Tower Research Capital LLC TRC now owns 15,128 shares of the company’s stock valued at $52,000 after acquiring an additional 11,708 shares in the last quarter. Finally, Ergoteles LLC bought a new stake in shares of Sutro Biopharma in the 2nd quarter valued at $54,000. Institutional investors own 96.99% of the company’s stock.

Insider Transactions at Sutro Biopharma

In other news, insider Nicki Vasquez sold 12,185 shares of the business’s stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $5.00, for a total value of $60,925.00. Following the transaction, the insider now owns 12,803 shares in the company, valued at approximately $64,015. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 6.90% of the company’s stock.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc operates as a clinical-stage oncology company. It develops site-specific and novel-format antibody drug conjugates (ADC) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. The company's product candidates include STRO-001, an ADC directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials.